| A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM (NCT04730505) | Celgene | 2021-02-04 |
| Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner (NCT05381077) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2021-02-02 |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb (NCT04649359) | Pfizer | 2021-02-02 |
| Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients (NCT04783038) | Mayo Clinic | 2021-01-27 |
| Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (NCT04714827) | Shanxi Province Cancer Hospital | 2021-01-22 |
| MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey (NCT04727294) | HealthTree Foundation | 2021-01-22 |
| A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice (NCT04659798) | Takeda | 2021-01-22 |
| Heart Rate Variability, Vagus Nerve and Cancer (NCT04718610) | Centre Hospitalier Henri Duffaut - Avignon | 2021-01-12 |
| Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma (NCT04150692) | Washington University School of Medicine | 2021-01-08 |
| The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 (NCT04746092) | Tel-Aviv Sourasky Medical Center | 2021-01-06 |
| Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation (NCT04589286) | University of California, San Francisco | 2020-12-29 |
| Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment (NCT05858203) | Regina Elena Cancer Institute | 2020-12-22 |
| Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin (NCT04549363) | GlaxoSmithKline | 2020-12-21 |
| Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT (NCT05928156) | Duke University | 2020-12-17 |
| Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma (NCT04805203) | Intergroupe Francophone du Myelome | 2020-12-16 |
| A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04586426) | Janssen Research & Development, LLC | 2020-12-15 |
| FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM) (NCT04349358) | Centre Georges Francois Leclerc | 2020-12-15 |
| Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (NCT04671251) | Avalo Therapeutics, Inc. | 2020-12-15 |
| Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients (NCT04604158) | Gillian Gresham | 2020-12-02 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT04445701) | Arch Oncology | 2020-11-30 |
| Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI (NCT04493411) | University of Texas Southwestern Medical Center | 2020-11-30 |
| Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma (NCT04637269) | Xinqiao Hospital of Chongqing | 2020-11-17 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) (NCT04557150) | Hoffmann-La Roche | 2020-11-11 |
| Physical Activity for Myeloma Autograft Longitudinal Study (NCT03946332) | Centre Hospitalier Universitaire, Amiens | 2020-11-10 |
| Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT04570631) | AbbVie | 2020-11-05 |
| Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes (NCT04271930) | Medical College of Wisconsin | 2020-11-01 |
| Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI) (NCT04609150) | Assistance Publique - Hôpitaux de Paris | 2020-11-01 |
| FT538 in Subjects With Advanced Hematologic Malignancies (NCT04614636) | Fate Therapeutics | 2020-10-17 |
| The clonoSEQ® Watch Registry (NCT04545333) | Adaptive Biotechnologies | 2020-10-13 |
| Multiple Myeloma Turkish Prospective Patient Registry (NCT04143932) | Turkish Hematology Association | 2020-10-10 |
| A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (NCT04398745) | GlaxoSmithKline | 2020-10-09 |
| MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma (NCT04552743) | Surbhi Sidana, MD | 2020-10-05 |
| Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy (NCT04140162) | University of Michigan Rogel Cancer Center | 2020-10-05 |
| Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (NCT04484623) | GlaxoSmithKline | 2020-10-01 |
| Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care (NCT04111809) | Assistance Publique - Hôpitaux de Paris | 2020-09-29 |
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT04543305) | Prelude Therapeutics | 2020-09-28 |
| Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (NCT04483739) | European Myeloma Network B.V. | 2020-09-25 |
| Virtual Exercise for Multiple Myeloma (NCT04484714) | University of Alberta | 2020-09-15 |
| MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (NCT04555551) | Memorial Sloan Kettering Cancer Center | 2020-09-08 |
| Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma (NCT04537442) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2020-09-03 |
| A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide (NCT04497961) | Memorial Sloan Kettering Cancer Center | 2020-08-28 |
| The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study (NCT04513639) | Oslo University Hospital | 2020-08-27 |
| A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT04394650) | Juno Therapeutics, a Subsidiary of Celgene | 2020-08-18 |
| Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases (NCT04504526) | First Affiliated Hospital of Fujian Medical University | 2020-08-07 |
| Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma (NCT04277845) | Samsung Medical Center | 2020-08-06 |
| Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (NCT03720041) | University of Leeds | 2020-08-04 |
| Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma (NCT04376957) | Hamilton Health Sciences Corporation | 2020-08-01 |
| Long Non-coding RNA (lncRNA) ZFAS1-Mediated Mechanism of Roasted Nux Vomica in Intervening Bortezomib-Induced Peripheral Neuropathy (NCT07614243) | The First Affiliated Hospital of Zhejiang Chinese Medical University | 2020-08-01 |
| Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation (NCT06425276) | CASI Pharmaceuticals (China) Co., Ltd. | 2020-07-24 |
| A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma (NCT04499339) | Wuerzburg University Hospital | 2020-07-22 |
| Myeloma Novel Drug Discovery Ver 1.2 (NCT05968417) | Institute of Cancer Research, United Kingdom | 2020-07-22 |
| Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry (NCT05556928) | University of Alabama at Birmingham | 2020-07-21 |
| MMRF CureCloud Research Initiative (NCT03657251) | Multiple Myeloma Research Foundation | 2020-07-14 |
| Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer (NCT04478123) | Memorial Sloan Kettering Cancer Center | 2020-07-14 |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT (NCT04150965) | Multiple Myeloma Research Consortium | 2020-07-10 |
| KRDI in Transplant-Eligible MM (NCT04430894) | Massachusetts General Hospital | 2020-07-10 |
| A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders (NCT03959358) | University Health Network, Toronto | 2020-07-03 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889) | Medigene AG | 2020-07-02 |
| COVID-19 Infection and Multiple Myeloma (NCT04492371) | Stichting European Myeloma Network | 2020-07-01 |
| Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma (NCT04459416) | Memorial Sloan Kettering Cancer Center | 2020-06-30 |
| Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT04447573) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-06-30 |
| A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (NCT04181827) | Janssen Research & Development, LLC | 2020-06-12 |
| Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM (NCT07084896) | GlaxoSmithKline | 2020-06-08 |
| Multiple Myeloma (MM) Quality of Life (QOL) Study (NCT04388735) | Massachusetts General Hospital | 2020-06-01 |
| A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM (NCT04412889) | Hebei Yanda Ludaopei Hospital | 2020-06-01 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule (NCT04275583) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-05-28 |
| A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (NCT04196491) | Celgene | 2020-05-27 |
| Digital Life Coaching for Myeloma Patients Undergoing Transplantation (NCT04432818) | University of California, San Francisco | 2020-05-20 |
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM (NCT04176718) | Andrew Yee, MD | 2020-05-18 |
| A Study of Ninlaro in Real World Clinical Practice in China (NCT04328662) | Takeda | 2020-05-18 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084) | Celularity Incorporated | 2020-05-12 |
| Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (NCT04246047) | GlaxoSmithKline | 2020-05-07 |
| ASH Research Collaborative Data Hub (NCT05775224) | ASH Research Collaborative | 2020-04-29 |
| CAR-T Cells in the Treatment of Malignant Hematological Tumors (NCT05619861) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-27 |
| Precision Medicine for Patients With Identified Actionable Mutations (NCT04111107) | Wake Forest University Health Sciences | 2020-04-22 |
| Detection and Pathogenesis of Novel Protein F (NCT04338386) | Wuhan Asia Heart Hospital | 2020-04-15 |
| Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) (NCT04184050) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-04-13 |
| Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (NCT04083898) | Washington University School of Medicine | 2020-04-03 |
| Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04162210) | GlaxoSmithKline | 2020-04-02 |
| A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (NCT05066646) | Nanjing IASO Biotechnology Co., Ltd. | 2020-04-01 |
| COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (NCT04354246) | Compugen Ltd | 2020-03-31 |
| Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health (NCT04000880) | University of Alabama at Birmingham | 2020-03-04 |
| Study of CAR-T Therapy in Older Patients (NCT04300998) | Memorial Sloan Kettering Cancer Center | 2020-03-04 |
| Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04496011) | Federal University of Health Science of Porto Alegre | 2020-03-02 |
| Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma (NCT04288765) | Grupo Cooperativo de Hemopatías Malignas | 2020-03-01 |
| Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment (NCT04309942) | Centre Hospitalier Universitaire de Nīmes | 2020-03-01 |
| Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma (NCT03490084) | Assistance Publique - Hôpitaux de Paris | 2020-02-25 |
| Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients (NCT04379817) | Jules Bordet Institute | 2020-02-25 |
| Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (NCT04280328) | Corvus Pharmaceuticals, Inc. | 2020-02-20 |
| Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma (NCT04248244) | Case Comprehensive Cancer Center | 2020-02-17 |
| A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma (NCT04244656) | CRISPR Therapeutics AG | 2020-01-22 |
| BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma (NCT04236011) | Shanghai Changzheng Hospital | 2020-01-16 |
| Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (NCT04113018) | Wake Forest University Health Sciences | 2020-01-10 |
| Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma (NCT04163107) | Norwegian University of Science and Technology | 2020-01-07 |
| Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease (NCT01125449) | Situs Cancer Research Center | 2020-01-01 |
| Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma (NCT04212858) | Assiut University | 2020-01-01 |
| Plasma-free Replacement in Patients With Multiple Myeloma (NCT05251896) | Zhongnan Hospital | 2020-01-01 |
| A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma (NCT04121260) | Janssen Research & Development, LLC | 2019-12-25 |